September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Successful treatment of recurrent ocular surface squamous neoplasia (OSSN) with topical cidofovir
Author Affiliations & Notes
  • Matthew Hochuen Ip
    Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
    Department of Ophthalmology, Prince of Wales Hospital, Sydney, New South Wales, Australia
  • Robert George
    South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales, Australia
  • William Rawlinson
    Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
    South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales, Australia
  • Minas T Coroneo
    Department of Ophthalmology, Prince of Wales Hospital, Sydney, New South Wales, Australia
    Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Matthew Ip, None; Robert George, None; William Rawlinson, None; Minas Coroneo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Matthew Hochuen Ip, Robert George, William Rawlinson, Minas T Coroneo; Successful treatment of recurrent ocular surface squamous neoplasia (OSSN) with topical cidofovir. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Despite the success of topical medical treatments, particularly with Interferon alpha-2b in treatment of OSSN, there is a failure rate of ~2%. A previous study2 showed OSSN responds to cidofovir (CDV), although our data showed no herpes viruses present in OSSN1. We have previously demonstrated that 6.5% of OSSN specimens are HPV-positive1, and considered the possibility that patients unresponsive to interferon may be HPV-positive and respond to antiviral therapy with CDV.

Methods : A single center retrospective observational case series was performed to evaluate the efficacy of topical CDV for treatment of recurrent OSSN in 7 eyes of 7 patients. Each patient had been previously diagnosed with OSSN utilizing slit-lamp examination confirmed with histopathology, and had failed other interventions including Interferon alpha-2b. Each patient was treated with 2.5mg/ml TDS topical CDV for a period of 4-6 weeks. Patients were then reviewed clinically with slit-lamp examination and photography to look for recurrence.

Results : Topical CDV was effective in 6 out of 7 eyes treated, with improved clinical appearance. After 1-month of CDV treatment, each of the 6 eyes demonstrated a marked reduction in mass size. Furthermore, no residual scar tissue was visualized (Figure 1 and 2). The mean follow-up with no clinical relapse is currently 6.4 months, with a range of follow-up of 1-12 months. In 1/7 cases we detected high risk HPV in a biopsy specimen using a hybrid capture assay. A further 5/7 were negative for high risk HPV using PCR, and 1/7 remains untested.

Conclusions : Topical CDV appears to be effective for treatment-refractive OSSN in the short-medium term. The efficacy of CDV raises the possibility of a viral etiology of OSSN in cases resistant to treatment with Interferon Alfa-2b.

1. Woods M et al. Cornea 2013;54:8069-8078.
2. Sherman MD et al. Am J Ophthal 2002;134:432-3.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Figure 1. The initial slit-lamp photograph of the right nasal conjunctiva of one patient.

Figure 1. The initial slit-lamp photograph of the right nasal conjunctiva of one patient.

 

Figure 2. A comparative clinical photograph of the right nasal conjunctiva 12 months after biopsy and topical cidofovir administration for 6 weeks.

Figure 2. A comparative clinical photograph of the right nasal conjunctiva 12 months after biopsy and topical cidofovir administration for 6 weeks.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×